Tin tức & Cập nhật

First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.

A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.

Stereotactic body radiotherapy (SBRT) is a safe and effective alternative to hyperfractionated accelerated radiotherapy (HART) in the treatment of limited-stage small-cell lung cancer (LS-SCLC), suggests a recent study.

Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.

The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.